Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilostazol vs Clopidogrel with Aspirin in Minor Stroke/TIA
NCT06591351Phase 3Recruiting
- Sponsor
- Kafrelsheikh University
- Start
- May 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of cilostazol in ischemic stroke and Transient Ischemic Attack (TIA) (2 arms), sponsored by Kafrelsheikh University. Primary endpoints: Rate of new stroke at 90 days and Rate of drug hemorrhagic complications at 90 days. Started May 2022; status: recruiting.
02
Drugs
cilostazol
03
Conditions
ischemic strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT06591351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06591351.